Compared with the conventional biomarker CEA for clinical use, the combination of these three explored biomarkers can improve the predictive performance (AUROC) for advanced CRC from 0.643 to 0.727 (Table 3 and Figure 6). Here, CEACAM5 is linked to colorectal carcinoma.